Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis
Li M, Chen P, Li J, Chu R, Xie D, Wang H
The Journal of clinical endocrinology and metabolism · 96 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2014-04-29 · J Clin Endocrinol Metab · vol. 99 · número 7 · págs. 2327–2336
- Editorial
- Oxford University Press
- Citado
- 120 citas · más que el 87% de estudios similares · 2.2× el promedio de su campo
- Referencias
- 87 trabajos
- Acceso
- De pago
- Áreas de investigación
- Vitamin D Research Studies · Nutritional Studies and Diet · Global Cancer Incidence and Screening
- Palabras clave
- 25-hydroxyvitamin D, vitamin D status, cancer prognosis, overall survival, colorectal cancer, breast cancer, lymphoma, cancer-specific mortality, disease-free survival, circulating biomarkers
- MeSH
- humans, neoplasms, vitamin d, prognosis, case-control studies, cohort studies, female, male
6 autores
- Mian Li🇨🇳Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences; University of Chinese Academy of Sciences
- Peizhan Chen🇨🇳Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences; University of Chinese Academy of Sciences
- Jingquan Li🇨🇳Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences; University of Chinese Academy of Sciences
- Ruiai Chu🇨🇳Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences; University of Chinese Academy of Sciences
- Dong Xie🇨🇳Chinese Academy of Sciences; ShanghaiTech University; Shanghai Institutes for Biological Sciences; University of Chinese Academy of Sciences
- Hui Wang🇨🇳 · autor de correspondenciaChinese Academy of Sciences; ShanghaiTech University; Shanghai Institutes for Biological Sciences; University of Chinese Academy of Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Context
Circulating levels of 25-hydroxyvitamin D [25(OH)D] may affect the prognosis of cancer patients; however, the epidemiological results are not consistent.
Objective
To perform a meta-analysis of all published studies to assess the associations of circulating 25(OH)D levels measured at or near the time of diagnosis and outcomes for cancer patients.
Data sources
Searches of the PubMed and MEDLINE databases were performed and updated to December 2013.
Study selection
Studies reporting an association between circulating 25(OH)D levels at or near the time of diagnosis and outcomes for the patients were included.
Data extraction
Data extraction was performed independently by two authors, and conflicts were resolved by a third investigator.
Data synthesis
Included in the meta-analysis were 25 studies with 17 332 cases. Significant associations between circulating 25(OH)D levels at or near the time of diagnosis and the outcomes for cancer patients were found. The pooled hazard ratio for the highest vs the lowest quartile of circulating 25(OH)D levels was 0.55 (95% confidence interval [CI] = 0.33-0.91) for overall survival of colorectal cancer patients, 0.63 (95% CI = 0.51-0.77) for breast cancer patients, and 0.48 (95% CI = 0.36-0.64) for lymphoma patients. Higher 25(OH)D levels were significantly associated with reduced cancer-specific mortality for patients with colorectal cancer (P = .005) and lymphoma (P < .001) and improved disease-free survival for patients with breast cancer (P < .001) or lymphoma (P < .05). A 10-nmol/L increment in circulating 25(OH)D levels conferred a hazard ratio of 0.96 (95% CI = 0.95-0.97) for overall survival of the cancer patients.
Conclusions
The results indicate that cancer patients with higher circulating 25(OH)D levels at or near the time of diagnosis have better outcomes.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.